Issue link: https://www.e-digitaleditions.com/i/1546950
20 OctOber 2026 Inhalation The transition to low-GWP propellants for MDIs Orbia Fluor & Energy Materials' Pharma business unit is advancing the transition to sustainable inhala- tion therapies through Zephex ® 152a, its low-GWP medical propellant designed for use in metered dose inhalers (MDIs). With significantly lower global warming potential compared to traditional propel- lants, Zephex 152a can enable pharmaceutical com- panies to reduce the carbon footprint of their MDIs while maintaining established inhaler performance and patient experience. Orbia is investing in large- scale manufacturing capacity and supply reliability to support global demand as respiratory markets move toward environmentally responsible solutions. Backed by over 30 years of experience, robust qual- ity systems and regulatory alignment, Zephex 152a is positioned to help the industry meet sustainability goals without compromising therapeutic delivery. Orbia United Kingdom www.Orbia-FEM.com A PFAS-free MDI coated-can patent In January of 2026, the European Patent office granted a patent for the first 100% PFAS-free, traditionally sprayed-coated MDI can. is product has been filled using 134a as well as both new-generation propellants, 1234ze and 152a, showing successful pharma results in all three cases. As deeper PFAS bans lurk, this prod- uct can provide a safe alternative for the inhalation industry as it seeks the lowest risk path. For more information, please contact Randy Churchill. Or visit us at our RDD 2026 booth or at biomerics.com. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com Supplying low-GWP medical propellant HFO-1234ze(E), GMP e transition to low global warming potential (GWP) propellant is no longer hypothetical. e world's first pressurized metered dose inhalers (pMDIs) using the low-GWP medical propellant HFO-1234ze(E), GMP supplied by Solstice have been approved for patient use in the United Kingdom, Europe, New Zealand and Australia. In addition, companies across the industry have announced that they are working with the next generation of propellant. As a low- GWP propellant supplier, Solstice Advanced Materi- als works with companies of various sizes and business models on the transition to low-GWP propellant because we believe sustainable respiratory care ben- efits from a wide range of options reaching patients. Solstice Advanced Materials UK: +44 7976 412142 Allan.Grossart@Solstice.com www.solstice.com Smart, breath-actuated mesh nebulizer HCmed is a strategic solution provider in inhaled drug delivery, partnering with pharma to address therapeutic challenges across a broad range of dis- ease areas. We co-create tailored combination prod- ucts to optimize deposition and therapeutic efficacy. Our AdheResp is the first US FDA 510(k)-cleared breath-actuated mesh nebulizer with built-in con- nectivity, engineered for high delivery efficiency. To meet growing demand, HCmed expanded manufac- turing capacity this year and established a Japan sub- sidiary, serving as your trusted partner from concept through commercialization. HCmed Innovations Co., Ltd. Taiwan: +886 2 27326596 info@hcmed-inno.com www.hcmed-inno.com

